Buy Rating Justified by Arcturus Therapeutics' Market Potential and Strong Vaccine Efficacy
H.C. Wainwright Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $63
Arcturus Therapeutics Price Target Maintained With a $63.00/Share by HC Wainwright & Co.
Arcturus Therapeutics Analyst Ratings
Wells Fargo Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $58
CCORF Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $72
CCORF Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $72
Leerink Partners Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating
Arcturus Therapeutics Analyst Ratings
William Blair Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating
CCORF Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $72
Buy Rating Affirmed: Arcturus Therapeutics' Promising Cystic Fibrosis Program Progress
CCORF Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $72
Arcturus Therapeutics Price Target Announced at $70.00/Share by Leerink Partners
Arcturus Therapeutics Analyst Ratings
Arcturus Therapeutics Analyst Ratings
Arcturus Therapeutics: Buy Rating Affirmed Amid Kostaive Launch and ARCT-810 Clinical Advancements
Arcturus Therapeutics Analyst Ratings
Piper Sandler Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $140
Arcturus Therapeutics (ARCT) Receives a Buy From Piper Sandler